Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4501
FitLife Brands
FTLF
$91.1M
| $100K | ﹤0.01% |
6,164
+538
| +10% | +$9.89K |
|
|
ETOR
4502
eToro Group
ETOR
$2.33B
| $100K | ﹤0.01% |
2,853
-447
| -14% | -$17.3K |
|
4503
ProShares Ultra QQQ
QLD
$13.9B
| $100K | ﹤0.01% |
1,422
-118
| -8% | -$8.36K |
|
4504
FT Vest US Equity Buffer ETF March
FMAR
$1.16B
| $99.8K | ﹤0.01% |
2,102
-2,370
| -53% | -$111K |
|
4505
CALL
Coca-Cola Europacific Partners
CCEP
$47.1B
| $99.8K | ﹤0.01% |
+1,100
| New | +$99.4K |
|
4506
PUT
DexCom
DXCM
$33.8B
| $99.6K | ﹤0.01% |
1,500
-34,900
| -96% | -$2.26M |
|
4507
Suzano
SUZ
$9.66B
| $99.5K | ﹤0.01% |
10,650
| – | – |
|
|
CV
4508
CapsoVision Inc
CV
$330M
| $97.7K | ﹤0.01% |
9,136
+943
| +12% | +$6.53K |
|
4509
Alto Ingredients
ALTO
$323M
| $96.8K | ﹤0.01% |
33,605
-648
| -2% | -$1.22K |
|
4510
AirSculpt Technologies
AIRS
$231M
| $96.7K | ﹤0.01% |
48,843
+25,461
| +109% | +$155K |
|
4511
Nerdy
NRDY
$95M
| $96.1K | ﹤0.01% |
92,448
+8,196
| +10% | +$9.24K |
|
4512
GSK
GSK
$102B
| $96.1K | ﹤0.01% |
1,959
-47,797
| -96% | -$2.23M |
|
|
FLNA
4513
Filana Therapeutics
FLNA
$46.9M
| $96K | ﹤0.01% |
48,462
+48,371
| +53,155% | +$155K |
|
4514
Wrap Technologies
WRAP
$104M
| $95.8K | ﹤0.01% |
+40,245
| New | +$97K |
|
4515
State Street SPDR S&P Insurance ETF
KIE
$678M
| $95.8K | ﹤0.01% |
+1,592
| New | +$93.7K |
|
4516
FT Vest US Equity Enhance & Moderate Buffer ETF January
XJAN
$41.9M
| $95.3K | ﹤0.01% |
2,588
-3,124
| -55% | -$114K |
|
4517
Chegg
CHGG
$92.8M
| $94.9K | ﹤0.01% |
102,087
-430
| -0.4% | -$469 |
|
4518
AllianzIM US Equity 6 Month Floor5 Jan/Jul ETF
FLJJ
$8.59M
| $94.4K | ﹤0.01% |
2,947
| – | – |
|
4519
Roundhill Generative AI & Technology ETF
CHAT
$1.85B
| $94.3K | ﹤0.01% |
1,600
-65,660
| -98% | -$4.07M |
|
4520
Nautilus Biotechnolgy
NAUT
$113M
| $94.1K | ﹤0.01% |
48,254
| – | – |
|
4521
Aemetis
AMTX
$123M
| $93.8K | ﹤0.01% |
67,455
+67,453
| +3,372,650% | +$136K |
|
4522
State Street SPDR Portfolio Intermediate Term Corporate Bond ETF
SPIB
$11.5B
| $92.5K | ﹤0.01% |
2,736
| – | – |
|
4523
FT Vest US Equity Deep Buffer ETF September
DSEP
$355M
| $92.3K | ﹤0.01% |
+2,056
| New | +$91.4K |
|
4524
CALL
Unilever
UL
$134B
| $92.1K | ﹤0.01% |
+1,408
| New | +$94.6K |
|
4525
Kewaunee Scientific
KEQU
$104M
| $91.9K | ﹤0.01% |
+2,457
| New | +$99.9K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.